Cancer therapy-induced ototoxicity: Current challenges and emerging management strategies

Abstract

Cochleovestibular impairment is a debilitating sequela of oncological intervention, resulting from multifaceted organic damage to the inner ear. Clinically manifesting as sensorineural hearing loss and vestibular dysfunction, ototoxicity significantly compromises cognitive health and long-term quality of life. Despite its prevalence, early detection and prophylactic intervention remain clinically suboptimal. This review provides a comprehensive analysis of the molecular pathogenesis and risk factors—including age, specific genetic polymorphisms, and cumulative dosage—associated with various cancer modalities such as platinum-based chemotherapy, radiotherapy, and emerging immunotherapies. We specifically evaluate the cellular mechanisms of cisplatin-induced irreversible damage to the stria vascularis and hair cells. Furthermore, this article critiques current clinical monitoring protocols, advocating for the integration of baseline audiological screening and high-frequency auditory assessments as mandatory standards of care. Finally, we synthesize the current therapeutic landscape, ranging from established otoprotective agents and cochlear implants to novel candidate drugs in the preclinical pipeline. By bridging mechanistic research with translational evidence, this review emphasizes a precision-medicine approach to balance therapeutic efficacy with the preservation of auditory integrity for cancer survivors.

Keywords

biomaterials / cancer therapy / otoprotective strategies / ototoxicity / risk factors

References

[1] Freyer DR, Brock PR, Chang KW, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health. 2020; 4(2): 141-150.

[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians. 2024; 74(3): 229-263.

[3] Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021; 18(10): 663-672.

[4] Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol. 2022; 79:102203.

[5] Trendowski MR, El Charif O, Dinh PC, Travis LB, Dolan ME. Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. 2019; 25(4): 1147-1155.

[6] Bukhari AF, Zawawi F. The impact of hearing loss and cochlear implantation on the quality of life in children. Int J Pediatr Otorhinolaryngol. 2024; 184:112069.

[7] Podury A, Jiam NT, Kim M, Donnenfield JI, Dhand A. Hearing and sociality: the implications of hearing loss on social life. Front Neurosci. 2023; 17:1245434.

[8] Paulino A, Mahajan A, Mangona V, et al. RO-03 ototoxicity and cohlear sparing in children with medulloblastoma: proton vs. photon radiotherapy. Neuro-Oncology. 2016; 18(suppl 3): iii159.

[9] Zou P, Hua C, Uh J, Conklin H, Merchant T, Sitaram R. IMG-01. Longitudinal fMRI of visual, auditory and motor function in pediatric craniopharyngioma sfter treatment with proton radiotherapy. Neuro-Oncology. 2023; 25(suppl 1): i46.

[10] Zhang ZJ, Saito T, Kimura Y, Sugimoto C, Ohtsubo T, Saito H. Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood–inner ear barrier in mice. Brain Res. 2000; 852(1): 116-126.

[11] Nader ME, Myers JN, Gidley PW. Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis. J Immunother Cancer. 2017; 5(1):24.

[12] Gambichler T, Seifert C, Lehmann M, Lukas C, Scheel C, Susok L. Concurrent Vogt–Koyanagi–Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy. 2020; 12(7): 439-444.

[13] Miller ZA, Mueller A, Kim T, et al. Lidocaine induces apoptosis in head and neck squamous cell carcinoma through activation of bitter taste receptor T2R14. Cell Rep. 2023; 42(12):113437.

[14] Beukes EW, Manchaiah V, Baguley DM, Allen PM, Andersson G. Internet-based interventions for adults with hearing loss, tinnitus and vestibular disorders: a protocol for a systematic review. Syst Rev. 2018; 7(1): 205.

[15] Hammami MB, Eggers SDZ, Madhavan A, Montalvo MJ, Pittock SJ, Dubey D. Paraneoplastic cochleovestibulopathy: clinical presentations, oncological and serological associations. J Neurol Neurosurg Psychiatry. 2021; 92(11): 1181-1185.

[16] Larsen PA, Amidi A, Ghith N, Winther JF, Pedersen C. Quality of life of adolescent and adult survivors of childhood cancer in Europe—a systematic review. Int J Cancer. 2023; 153(7): 1356-1375.

[17] Cunningham CL, Müller U. Molecular structure of the hair cell mechanoelectrical transduction complex. Cold Spring Harb Perspect Med. 2019; 9(5):a033167.

[18] Dewey JB, Xia A, Müller U, Belyantseva IA, Applegate BE, Oghalai JS. Mammalian auditory hair cell bundle stiffness affects frequency tuning by increasing coupling along the length of the cochlea. Cell Rep. 2018; 23(10): 2915-2927.

[19] Sun S, Babola T, Pregernig G, et al. Hair cell Mechanotransduction regulates spontaneous activity and spiral ganglion subtype specification in the auditory system. Cell. 2018; 174(5): 1247-1263.

[20] Mittal R, Debs LH, Nguyen D, et al. Signaling in the auditory system: implications in hair cell regeneration and hearing function. J Cell Physiol. 2017; 232(10): 2710-2721.

[21] Juhn SK, Rybak LP, Prado S. Nature of blood-labyrinth barrier in experimental conditions. Ann Otol Rhinol Laryngol. 1981; 90(2): 135-141.

[22] Noman A, Mukherjee S, Le T. Manipulating the blood labyrinth barrier with mannitol to prevent cisplatin-induced hearing loss. Hear Res. 2022; 426:108646.

[23] Shi X, Wang Z, Ren W, et al. LDL receptor-related protein 1 (LRP1), a novel target for opening the blood-labyrinth barrier (BLB). Signal Transduct Target Ther. 2022; 7(1):175.

[24] Nyberg S, Abbott NJ, Shi X, Steyger PS, Dabdoub A. Delivery of therapeutics to the inner ear: the challenge of the blood-labyrinth barrier. Sci Transl Med. 2019; 11(482):eaao0935.

[25] Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston Ototoxicity Scale. JCO. 2012; 30(19): 2408-2417.

[26] World Health Organization, ed. World Report on Hearing. 1st ed. World Health Organization; 2021.

[27] Song Z, Wu Y, Tang D, et al. Tinnitus is associated with extended high-frequency hearing loss and hidden high-frequency damage in young patients. Otol Neurotol. 2021; 42(3): 377-383.

[28] Prayuenyong P, Taylor JA, Pearson SE, et al. Vestibulotoxicity associated with platinum-based chemotherapy in survivors of cancer: a scoping review. Front Oncol. 2018; 8: 363.

[29] El Charif O, Mapes B, Trendowski MR, et al. Clinical and genome-wide analysis of cisplatin-induced tinnitus implicates novel ototoxic mechanisms. Clin Cancer Res. 2019; 25(13): 4104-4116.

[30] Phillips OR, Baguley DM, Pearson SE, Akeroyd MA. The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review. J Cancer Surviv. 2023; 17(1): 40-58.

[31] Maru D, Malky GA. Current practice of ototoxicity management across the United Kingdom (UK). Int J Audiol. 2018; 57(sup4): S29-S41.

[32] Pearson SE, Caimino C, Shabbir M, Baguley DM. The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study. J Cancer Surviv. 2022; 16(5): 976-987.

[33] Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and Nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010; 176(3): 1169-1180.

[34] Jeon H, Song IS, Park JG, et al. Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study. Aquat Toxicol. 2023; 260:106573.

[35] Wang X, Zhou Y, Wang D, et al. Cisplatin-induced ototoxicity: from signaling network to therapeutic targets. Biomed Pharmacother. 2023; 157:114045.

[36] Gu J, Tong L, Lin X, et al. The disruption and hyperpermeability of blood-labyrinth barrier mediates cisplatin-induced ototoxicity. Toxicol Lett. 2022; 354: 56-64.

[37] Breglio AM, Rusheen AE, Shide ED, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017; 8(1): 1654.

[38] Sung CYW, Hayase N, Yuen PST, et al. Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity. Sci Adv. 2024; 10(30):eadk9878.

[39] Nan B, Zhao Z, Jiang K, Gu X, Li H, Huang X. Astaxanthine attenuates cisplatin ototoxicity in vitro and protects against cisplatin-induced hearing loss in vivo. Acta Pharm Sin B. 2022; 12(1): 167-181.

[40] Kitcher SR, Kirkwood NK, Camci ED, et al. ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity. JCI Insight. 2019; 4(15):e126764.

[41] Anfuso CD, Cosentino A, Agafonova A, et al. Pericytes of stria vascularis are targets of cisplatin-induced ototoxicity: new insights into the molecular mechanisms involved in blood-labyrinth barrier breakdown. IJMS. 2022; 23(24):15790.

[42] Oh GS, Kim HJ, Choi JH, et al. Activation of lipopolysaccharide–TLR4 signaling accelerates the ototoxic potential of cisplatin in mice. J Immunol. 2011; 186(2): 1140-1150.

[43] Waissbluth S, del Valle Á, Chuang A, Becker A. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol. 2018; 111: 174-179.

[44] Moke DJ, Luo C, Millstein J, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional north American cohort study. Lancet Child Adolesc Health. 2021; 5(4): 274-283.

[45] Burger AVM, Duinkerken CW, van Sluis KE, et al. Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer. Eur Arch Otorrinolaringol. 2024; 281(12): 6627-6635.

[46] Gamez ME, Blakaj DM, Bhateja P, et al. Audiological outcomes of weekly vs. triweekly cisplatin in head and neck cancer with cochlear-sparing intensity-modulated radiation therapy. Cancer. 2024; 16(12): 2228.

[47] Kuguyo O, Matimba A, Madziyire MG, et al. Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer. Future Oncol. 2024; 20(26): 1909-1924.

[48] Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys. 2007; 68(5): 1320-1325.

[49] Huang Y, Zhou H, An F, et al. The relevance of ototoxicity induced by radiotherapy. Radiat Oncol. 2023; 18(1): 95.

[50] He S, Yu H, He L, et al. Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors. Oral Oncol. 2024; 154:106827.

[51] Diepstraten FA, Bertram OMM, Helleman HW, et al. A retrospective evaluation of ototoxicity monitoring in a cohort of pediatric patients with solid tumors, treated in the Dutch National Cancer Center. Cancer Reports. 2024; 7(11):e70046.

[52] Attar M, Alqarni MS, Alsinnari YM, et al. The incidence and risk factors of cisplatin and carboplatin ototoxicity in pediatric oncology patients at tertiary oncology center. Indian J Surg Oncol. 2022; 13(4): 925-930.

[53] Sanchez VA, Dinh PC, Rooker J, et al. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv. 2023; 17: 27-39.

[54] Li K, Zhao Y, Cheng H, Yang J, Chien C. Ototoxicity among cisplatin, carboplatin, and oxaliplatin in zebrafish model. Environ Toxicol. 2024; 39(7): 4058-4065.

[55] Singu BS, Verbeeck RK, Pieper CH, Ette EI. Confirming the suitability of a gentamicin dosing strategy in neonates using the population pharmacokinetic approach with truncated sampling duration. Children. 2024; 11(8):898.

[56] Riggs LC, Brummett RE, Guitjens SK, Matz GJ. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1996; 106(4): 401-406.

[57] Schuette A, Lander DP, Kallogjeri D, et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2020; 146(2): 106-112.

[58] Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009; 6(11): 638-647.

[59] Tuknayat A, Thami GP, Gogia P, Bhutani M. Cyclophosphamide-induced hearing loss: reversibility and preventive strategies. Am J Ther. 2018; 25(6): e692-e695.

[60] Dong Y, Ding D, Jiang H, Shi JR, Salvi R, Roth JA. Ototoxicity of paclitaxel in rat cochlear organotypic cultures. Toxicol Appl Pharmacol. 2014; 280(3): 526-533.

[61] Xuan L, Sun B, Meng X, Liu C, Cong Y, Wu S. Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases. Cancer Biol Ther. 2020; 21(11): 990-993.

[62] Bucak A, Özdemir Ç, Kınar A, et al. Cabazitaxel's ototoxicity: an animal study and histopathologic research. J Cancer Res Ther. 2023; 19(Suppl 1): S314-S317.

[63] Moore B, Sheets G, Doss J, et al. Is methotrexate ototoxic? Investigating the ototoxic late effects of pediatric cancer treatment. Am J Audiol. 2023; 32(3): 657-664.

[64] Tang R, Yin J, Liu Y, Xue J. FLASH radiotherapy: a new milestone in the field of cancer radiotherapy. Cancer Lett. 2024; 587:216651.

[65] Zhang J, Xu A, Niu T, et al. A unique radioprotective effect of resolvin E1 reduces irradiation-induced damage to the inner ear by inhibiting the inflammatory response. Radiat Oncol. 2020; 15(1): 223.

[66] Chen L, Li J, Li K, et al. Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. Radiother Oncol. 2024; 190:109985.

[67] Scobioala S, Parfitt R, Matulat P, et al. The impact of the temporal sequence of cranial radiotherapy and platin-based chemotherapy on hearing impairment in pediatric and adolescent CNS and head-and-neck cancer patients: a report from the PanCareLIFE consortium. Int J Cancer. 2023; 154(2): 320-331.

[68] Liu Z, Luo Y, Guo R, et al. Head and neck radiotherapy causes significant disruptions of cochlear ribbon synapses and consequent sensorineural hearing loss. Radiother Oncol. 2022; 173: 207-214.

[69] Gao Y, Wu F, He W, Cai Z, Pang J, Zheng Y. Reactive oxygen species–related disruptions to cochlear hair cell and stria vascularis consequently leading to radiation-induced sensorineural hearing loss. Antioxid Redox Signal. 2024; 40(7–9): 470-491.

[70] Zhan L, Feng HF, Liu HQ, et al. Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management. Front Endocrinol. 2021; 12:649863.

[71] Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018; 19(9): e447-e458.

[72] Watanabe R, Hashimoto M. Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases. Ann Rheum Dis. 2022; 81(12):e262.

[73] Chen P, Li J, Tan H. Progress and challenges of immune checkpoint inhibitor-induced hypophysitis. J Clin Med. 2023; 12(10):3468.

[74] Osataphan SA, Awidi M, Jan YJ, et al. Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer. JCO. 2023; 41(16_suppl):e21125.

[75] Kaufman B, Abramov O, Ievko A, et al. Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer. Sci Adv. 2023; 9(21):eadg2809.

[76] Salvatori E, Lione L, Compagnone M, et al. Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. Npj Vaccines. 2022; 7(1): 15.

[77] Pai CCS, Simons DM, Lu X, et al. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2018; 129(1): 349-363.

[78] Rosner S, Agrawal Y, Sun DQ, et al. Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. J Immunother Cancer. 2020; 8(2):e001675.

[79] Boutros C, Peres E, Routier E, Robert C, Le Pajolec C. Severe ototoxicity associated with immune checkpoint inhibitors (ICI) in advanced melanoma. Eur J Cancer. 2022; 173: 204-206.

[80] Guven DC, Erul E, Kaygusuz Y, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023; 31(11): 624.

[81] Pignata S, Lorusso D, Joly F, et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021; 22(2): 267-276.

[82] Brooks B, Knight K. Ototoxicity monitoring in children treated with platinum chemotherapy. Int J Audiol. 2018; 57(sup4): S62-S68.

[83] Pasdelou MP, Byelyayeva L, Malmström S, et al. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Front Mol Neurosci. 2024; 17:1379743.

[84] Koch EAT, Nickel FT, Heinzerling L, Schulz YK, Berking C, Erdmann M. Immune checkpoint inhibitor-induced bilateral vestibulopathy. J Immunother. 2021; 44: 114-117.

[85] Stürmer SH, Lechner A, Berking C. Sudden otovestibular dysfunction in 3 metastatic melanoma patients treated with immune checkpoint inhibitors. J Immunother. 2021; 44(5): 193-197.

[86] King KA, Brewer CC. Clinical trials, ototoxicity grading scales and the audiologist's role in therapeutic decision making. Int J Audiol. 2018; 57(sup4): S19-S28.

[87] Soliman SE, D'Silva CN, Dimaras H, Dzneladze I, Chan H, Gallie BL. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: a retrospective noncomparative single-institute experience. Pediatr Blood Cancer. 2018; 65(5):e26931.

[88] Fetoni AR, Brigato F, de Corso E, et al. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity. Eur Arch Otorrinolaringol. 2022; 279(10): 4677-4686.

[89] Bass JK, Hua CH, Huang J, et al. Hearing loss in patients who received cranial radiation therapy for childhood cancer. JCO. 2016; 34(11): 1248-1255.

[90] Shahbazi M, Zhang X, Dinh PC, et al. Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer. Cancer Med. 2023; 12(3): 2999-3012.

[91] Henry JA, Griest S, Zaugg TL, et al. Tinnitus and hearing survey: a screening tool to differentiate bothersome tinnitus from hearing difficulties. Am J Audiol. 2015; 24(1): 66-77.

[92] Chattaraj A, Syed MP, Low CA, Owonikoko TK. Cisplatin-induced ototoxicity: a concise review of the burden, prevention, and interception strategies. JCO Oncol Pract. 2023; 19(5): 278-283.

[93] Sanchez VA, Dinh PC, Monahan PO, et al. Comprehensive audiologic analyses after cisplatin-based chemotherapy. JAMA Oncol. 2024; 10(7): 912.

[94] Lee DS, Travis EY, Wong SK, et al. Trends in ototoxicity monitoring among cisplatin-treated patients with cancer. J Cancer Surviv. 2024; 19(5): 1750-1760.

[95] Skarżyński H, Gos E, Raj-Koziak D, Skarżyński PH. Skarzynski tinnitus scale: validation of a brief and robust tool for assessing tinnitus in a clinical population. Eur J Med Res. 2018; 23(1): 54.

[96] Zeman F, Koller M, Schecklmann M, Langguth B, Landgrebe M, TRI Database Study Group. Tinnitus assessment by means of standardized self-report questionnaires: psychometric properties of the Tinnitus Questionnaire (TQ), the Tinnitus Handicap Inventory (THI), and their short versions in an international and multi-lingual sample. Health Qual Life Outcomes. 2012; 10(1):128.

[97] Asai K, Hiraizumi T, Hanzawa R. Reliability and validity of the Japanese version of the active-emphatic listening scale. BMC Psychol. 2020; 8(1): 59.

[98] Adeyemo AA, Adeolu J, Akinyemi JO, Omotade OO, Oluwatosin OM. Predictive model for aminoglycoside induced ototoxicity. Front Neurol. 2024; 15:1461823.

[99] Shetty S, Bhandary SK, Bhat V, Aroor R, Shetty J, Dattatreya T. Role of otoacoustic emission in early detection of cisplatin induced ototoxicity. Indian J Otolaryngol Head Neck Surg. 2022; 74(S1): 164-169.

[100] Neely ST, Rasetshwane DM, Gorga MP. Otoacoustic emissions: laboratory studies and clinical applications. J Acoust Soc Am. 2018; 143(3 suppl): 1809-1810.

[101] Solis-Angeles S, del Razo LM, Aguilar-Madrid G, et al. Occupational lead exposure ototoxicity evaluated with distortion-product otoacoustic emissions. Ear Hear. 2024; 45(2): 329-336.

[102] Garinis AC, Keefe DH, Hunter LL, et al. Chirp-evoked otoacoustic emissions and middle ear absorbance for monitoring ototoxicity in cystic fibrosis patients. Ear Hear. 2018; 39(1): 69-84.

[103] Bogacz A, Sinkiewicz A, Burduk P, Kozakiewicz-Rutkowska A, Kubala-Owieśny A. High-frequency audiometry in the diagnosis of tinnitus. Ir J Med Sci. 2024; 193(1): 383-388.

[104] Al-Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros. 2015; 14(2): 248-254.

[105] Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function As a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. JCO. 2007; 25(10): 1190-1195.

[106] Mishra SK, Saxena U, Rodrigo H. Hearing impairment in the extended high frequencies in children despite clinically normal hearing. Ear Hear. 2022; 43(6): 1653-1660.

[107] Drögemöller BI, Monzon JG, Bhavsar AP, et al. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017; 3(11): 1558-1562.

[108] Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. JCO. 2010; 28(10): 1788-1795.

[109] Dhillon S. Sodium thiosulfate: pediatric first approval. Pediatr Drugs. 2023; 25(2): 239-244.

[110] Li Y, Zhang T, Song Q, et al. Cisplatin ototoxicity mechanism and antagonistic intervention strategy: a scope review. Front Cell Neurosci. 2023; 17:1197051.

[111] Aschenbrenner DS. Drug approved to prevent cisplatin-associated ototoxicity in children. Am J Nurs. 2023; 123(1): 23.

[112] Lyu AR, Kim SJ, Park MJ, Park YH. CORM-2 reduces cisplatin accumulation in the mouse inner ear and protects against cisplatin-induced ototoxicity. J Adv Res. 2024; 64: 183-194.

[113] Liu J, Zhu L, Bao Y, et al. Injectable dexamethasone-loaded peptide hydrogel for therapy of radiation-induced ototoxicity by regulating the mTOR signaling pathway. J Control Release. 2024; 365: 729-743.

[114] Zhang J, Zhang W, Huang X, Li M, Yang H. Inhibition of inner ear macrophage phagocytosis alleviates cisplatin-induced ototoxicity. Commun Biol. 2025; 8(1): 1134.

[115] Sternasty K, Dhar S. Barriers to hearing aid adoption run deeper than the price tag. JAMA Otolaryngol Head Neck Surg. 2021; 147(6): 498.

[116] Hartley D, Rochtchina E, Newall P, Golding M, Mitchell P. Use of hearing aids and assistive listening devices in an older Australian population. J Am Acad Audiol. 2010; 21(10): 642-653.

[117] Jacobs M, Ryan H, Ellis C. Racial-ethnic disparities in hearing aid use: Price responsiveness among older adults with hearing loss. J Racial Ethn Health Disparities. 2023; 12: 489-498.

[118] Yoon CY, Lee J, Kong TH, Seo YJ. Effect of changes in the hearing aid subsidy on the prevalence of hearing loss in South Korea. Front Neurol. 2023; 14:1215494.

[119] Alberti G, Portelli D, Loteta S, Galletti C, D'Angelo M, Ciodaro F. Open-fitting hearing aids: a comparative analysis between open behind-the-ear and open completely-in-the-canal instant-fit devices. Eur Arch Otorrinolaringol. 2024; 281(11): 6009-6019.

[120] Liu CC, Livingstone D, Yunker WK. The role of bone conduction hearing aids in congenital unilateral hearing loss: a systematic review. Int J Pediatr Otorhinolaryngol. 2017; 94: 45-51.

[121] Diehl PU, Singer Y, Zilly H, et al. Restoring speech intelligibility for hearing aid users with deep learning. Sci Rep. 2023; 13(1):2719.

[122] Fontan L, le Coz M, Azzopardi C, Stone MA, Füllgrabe C. Improving hearing-aid gains based on automatic speech recognition. J Acoust Soc Am. 2020; 148(3): EL227-EL233.

[123] Sabin AT, McElhone D, Gauger D, Rabinowitz B. Modeling the intelligibility benefit of active noise cancelation in hearing devices that improve signal-to-noise ratio. Trends Hear. 2024; 28:23312165241260029.

[124] Siddiqui HUR, Saleem AA, Raza MA, Zafar K, Russo R, Dudley S. Automatic user preferences selection of smart hearing aid using BioAid. Sensors. 2022; 22(20):8031.

[125] Knoetze M, Manchaiah V, Oosthuizen I, Beukes E, Swanepoel DW. Perspectives on hearing aid cost and uptake for prescription and over-the-counter hearing aid users. Am J Audiol. 2024; 33(3): 942-952.

[126] Narayanan SK, Houmller SS, Wolff A, et al. Adapting to new hearing aids and hearing aid adjustments in adult Danish users. Am J Audiol. 2023; 32(3): 526-542.

[127] Araújo FDQM, Janaú LCJ, Nobre TT, Garcia Filho E, Cardoso JR, Ferreira DB. Tutorial sobre uso e manejo de próteses auditivas. Braz J Hea Rev. 2023; 6(2): 4917-4938.

[128] Carr K, Kihm J. MarkeTrak—tracking the pulse of the hearing aid market. Semin Hear. 2022; 43(4): 277-288.

[129] Marinelli JP, Sydlowski SA, Carlson ML. Cochlear implant awareness in the United States: a national survey of 15 138 adults. Semin Hear. 2022; 43(4): 317-323.

[130] Bass JK, Warren SE, Dillard SG, et al. Eligibility for cochlear implant candidacy evaluation in childhood cancer survivors. JAMA Oncol. 2025; 11(7): 794-796.

[131] Nassiri AM, Sorkin DL, Carlson ML. Current estimates of cochlear implant utilization in the United States. Otol Neurotol. 2022; 43(5): e558-e562.

[132] Kashio A, Takahashi H, Nishizaki K, Hara A, Yamasoba T, Moriyama H. cochlear implants in Japan: results of cochlear implant reporting system over more than 30 years. Auris Nasus Larynx. 2021; 48(4): 622-629.

[133] Eshraghi AA, Nazarian R, Telischi FF, Rajguru SM, Truy E, Gupta C. The cochlear implant: historical aspects and future prospects. Anat Rec. 2012; 295(11): 1967-1980.

[134] Hrncirik F, Roberts I, Sevgili I, Swords C, Bance M. Models of cochlea used in cochlear implant research: a review. Ann Biomed Eng. 2023; 51(7): 1390-1407.

[135] Carlson ML. Cochlear implantation in adults. N Engl J Med. 2020; 382(16): 1531-1542.

[136] Dornhoffer JR, Reddy P, Meyer TA, Schvartz-Leyzac KC, Dubno JR, McRackan TR. Individual differences in speech recognition changes after cochlear implantation. JAMA Otolaryngol Head Neck Surg. 2021; 147(3): 280.

[137] Mangan AR, Davis KP, Anzalone CL, Saadi RA, Dornhoffer JL, King DL. Assessing patient barriers to cochlear implantation. Otol Neurotol. 2022; 43(10): e1090-e1093.

[138] Alahmadi A, Abdelsamad Y, Al-zuraiqi B, Alghamdi S, Hagr A, Saleh E. Cochlear implantation in radiation-induced hearing loss: a systematic review. Otol Neurotol. 2023; 44(8): 767-774.

[139] Plontke SK, Fröhlich L, Wagner L, et al. How much cochlea do you need for cochlear implantation? Otol Neurotol. 2020; 41(5): 694-703.

[140] Miaskowski C, Mastick J, Paul SM, et al. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life. J Cancer Surviv. 2018; 12(2): 234-245.

[141] Tang LQ, Chen DP, Guo L, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018; 19(4): 461-473.

[142] Kim SB, Kim SY, Kim KH, Kim TN. Oxaliplatin-induced sudden hearing loss in a patient with pancreatic cancer. Korean J Gastroenterol. 2020; 76(5): 261-264.

[143] Malhotra NK, Aslam R, Lipman SP, Bilski VJ. Acute ototoxicity from a single infusion of oxaliplatin. Ear Nose Throat J. 2010; 89(6): 258-261.

[144] Oliveira PFD, Oliveira CS, Andrade JS, do Carmo Santos TF, de Oliveira-Barreto AC. Cancer treatment in determination of hearing loss. Braz J Otorhinolaryngol. 2016; 82(1): 65-69.

[145] van Assche IA, van Calsteren K, Huis In't Veld E, et al. Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study. EClinicalMedicine. 2024; 78:102922.

[146] Lim CC, Lu JL, Kulasegarah J. Osimertinib-induced hearing loss: an uncommon aftereffect of a novel drug—a case report. Egypt J Otolaryngol. 2022; 38(1):64.

[147] Cheng J, Wang L, Zhu LN, Wang L. Bilateral sensorineural hearing loss induced by regorafenib. J Clin Pharm Ther. 2019; 44(6): 963-965.

[148] Tampio AJF, Dhanireddy S, Sivapiragasam A, Nicholas BD. Bilateral sensorineural hearing loss associated with nivolumab therapy for stage IV malignant melanoma. Ear Nose Throat J. 2021; 100(3_suppl): 286S-291S.

[149] Keilty D, Khandwala M, Liu ZA, et al. Hearing loss after radiation and chemotherapy for CNS and head-and-neck tumors in children. JCO. 2021; 39(34): 3813-3821.

[150] Hsin CH, Tseng HC, Lin HP, Chen TH. Post-irradiation otitis media, rhinosinusitis, and their interrelationship in nasopharyngeal carcinoma patients treated by IMRT. Eur Arch Otorrinolaringol. 2016; 273(2): 471-477.

[151] Hitt R, Mesía R, Lozano A, et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs. radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol. 2022; 134:106087.

[152] Runge CL, Lyness JA, Gillison ML, et al. Self-perceived hearing outcomes with radiation and cisplatin or radiation and cetuximab for patients with human papilloma virus (HPV)-positive oropharyngeal cancer—results from NRG oncology RTOG 1016. Int J Radiat Oncol Biol Phys. 2026; 124(1): 61-69.

[153] Lu J, Li W, Du X, et al. Antioxidants reduce cellular and functional changes induced by intense noise in the inner ear and cochlear nucleus. JARO. 2014; 15(3): 353-372.

[154] Kim SK, Im GJ, An YS, Lee SH, Jung HH, Park SY. The effects of the antioxidant α-tocopherol succinate on cisplatin-induced ototoxicity in HEI-OC1 auditory cells. Int J Pediatr Otorhinolaryngol. 2016; 86: 9-14.

[155] Dey D, Ghosh S, Ray R, Hazra B. Polyphenolic secondary metabolites synergize the activity of commercial antibiotics against clinical isolates of β-lactamase-producing Klebsiella pneumoniae: plant polyphenols synergize antibiotics against K. pneumoniae. Phytother Res. 2016; 30(2): 272-282.

[156] Gu LT, Yang J, Su SZ, Liu WW, Shi ZG, Wang QR. Green tea polyphenols protects cochlear hair cells from ototoxicity by inhibiting notch Signalling. Neurochem Res. 2015; 40(6): 1211-1219.

[157] Haryuna TSH, Fauziah D, Anggraini S, Harahap MPH, Harahap J. Antioxidant effect of curcumin on the prevention of oxidative damage to the cochlea in an ototoxic rat model based on malondialdehyde expression. Int Arch Otorhinolaryngol. 2022; 26(1): e119-e124.

[158] Zong Y, Chen F, Li S, Zhang H. (−)-Epigallocatechin-3-gallate (EGCG) prevents aminoglycosides-induced ototoxicity via anti-oxidative and anti-apoptotic pathways. Int J Pediatr Otorhinolaryngol. 2021; 150:110920.

[159] Sekulic-Jablanovic M, Voronkova K, Bodmer D, Petkovic V. Combination of antioxidants and NFAT (nuclear factor of activated T cells) inhibitor protects auditory hair cells from ototoxic insult. J Neurochem. 2020; 154(5): 519-529.

[160] Tate AD, Antonelli PJ, Hannabass KR, Dirain CO. Mitochondria-targeted antioxidant mitoquinone reduces cisplatin-induced ototoxicity in Guinea pigs. Otolaryngol–Head Neck Surg. 2017; 156(3): 543-548.

[161] Han Z, Wang CP, Cong N, Gu YY, Ma R, Chi FL. Therapeutic value of nerve growth factor in promoting neural stem cell survival and differentiation and protecting against neuronal hearing loss. Mol Cell Biochem. 2017; 428(1–2): 149-159.

[162] Ranjbar N, Shahbazi A, Nourizadeh N, Namvar Arefi H, Kheirkhah MT. Relationship between serum levels of brain-derived neurotrophic factor (BDNF) and hearing loss and tinnitus. Indian J Otolaryngol Head Neck Surg. 2023; 75(S1): 507-513.

[163] Yu Q, Liu S, Guo R, et al. Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic factor–poly(dl -lactic acid- co -glycolic acid)-loaded hydrogel. ACS Nano. 2024; 18(8): 6298-6313.

[164] Vink HA, Ramekers D, Thomeer HGXM, Versnel H. Combined brain-derived neurotrophic factor and neurotrophin-3 treatment is preferred over either one separately in the preservation of the auditory nerve in deafened guinea pigs. Front Mol Neurosci. 2022; 15:935111.

[165] Blakley BW, Seaman M, Alenezi A. Brain-derived nerve growth factor in the cochlea—a reproducibility study. J Otolaryngol Head Neck Surg. 2020; 49(1): 37.

[166] Dilwali S, Lysaght A, Roberts D, Barker FG, McKenna MJ, Stankovic KM. Sporadic vestibular schwannomas associated with good hearing secrete higher levels of fibroblast growth factor 2 than those associated with poor hearing irrespective of tumor size. Otol Neurotol. 2013; 34(4): 748-754.

[167] Dilwali S, Landegger LD, Soares VYR, Deschler DG, Stankovic KM. Secreted factors from human vestibular schwannomas can cause cochlear damage. Sci Rep. 2015; 5(1):18599.

[168] Jeong M, Bojkovic K, Sagi V, Stankovic KM. Molecular and clinical significance of fibroblast growth factor 2 in development and regeneration of the auditory system. Front Mol Neurosci. 2021; 14:757441.

[169] Low W, Dazert S, Baird A, Ryan AF. Basic fibroblast growth factor (FGF-2) protects rat cochlear hair cells in organotypical culture from aminoglycoside injury. J Cell Physiol. 1996; 167(3): 443-450.

[170] Gu R, Longenecker RJ, Homan J, Kil J. Ebselen attenuates tobramycin-induced ototoxicity in mice. J Cyst Fibros. 2021; 20(2): 271-277.

[171] Kil J, Harruff EE, Longenecker RJ. Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hear Res. 2022; 413:108209.

[172] Martín-Saldaña S, Palao-Suay R, Aguilar MR, Ramírez-Camacho R, San Román J. Polymeric nanoparticles loaded with dexamethasone or α-tocopheryl succinate to prevent cisplatin-induced ototoxicity. Acta Biomater. 2017; 53: 199-210.

[173] Wang J, Wang C, Wang Q, et al. Microfluidic preparation of gelatin methacryloyl microgels as local drug delivery vehicles for hearing loss therapy. ACS Appl Mater Interfaces. 2022; 14(41): 46212-46223.

[174] Jung SY, Kim S, Kang Z, et al. Efficiency of a dexamethasone nanosuspension as an intratympanic injection for acute hearing loss. Drug Deliv. 2022; 29(1): 149-160.

[175] Pan C, Kang J, Hwang JS, et al. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. Nat Commun. 2021; 12(1):4960.

[176] Fritzsche S, Strauss C, Scheller C, Leisz S. Nimodipine treatment protects auditory hair cells from cisplatin-induced cell death accompanied by upregulation of LMO4. Int J Mol Sci. 2022; 23(10):5780.

[177] Sheth S, Sheehan K, Dhukhwa A, et al. Oral administration of caffeine exacerbates cisplatin-induced hearing loss. Sci Rep. 2019; 9(1):9571.

RIGHTS & PERMISSIONS

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.